- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05885191
True Ileal Amino Acid Digestibility of Tenebrio Molitor Larvae in Women
April 16, 2024 updated by: Diego Moretti
True Ileal Amino Acid Digestibility of Tenebrio Molitor Larvae Determined by Dual Stable Isotope Tracer Method in Young Women
Dietary protein intake of adequate quality is essential for human health.
Traditional animal source foods play a key role in providing high quality protein but are associated with a high burden on the environment.
Therefore, viable alternative protein sources are needed to be able to meet human nutritional needs for the rapidly increasing world population, while keeping food production within the planetary boundaries.
T. molitor (Yellow Mealworm larvae) is a sustainably produced and commercially available edible insect, which contains a high quantity of protein with a favorable amino acid profile.
Protein quality evaluation considers the amino acid composition as well as the ileal digestibility of the food's individual amino acids, to assess if human dietary requirements for essential amino acids can be met by the protein source.
The present study will measure the digestibility of essential amino acids from T. molitor with a minimally invasive dual stable isotope tracer method that follows a plateau-fed test meal protocol.
T. molitor will be intrinsically labelled with the stable isotope deuterium (2H), which will be given along with a reference amino acid mixture of known digestibility, labelled with the stable isotope carbon-13 (13C).
Based on the results from the present study, protein quality of T. molitor as a protein source for human nutrition can be assessed, allowing a direct comparison of this novel protein source to other protein sources, such as meat and legumes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zürich, Switzerland, 8092
- ETH Zurich, Laboratory of Human Nutrition
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Female aged between 18-45 years
- Normal BMI (18.5 - 25 kg/m2)
- Body weight < 60 kg
- Signed informed consent
- Able to communicate and comprehend English
- Are open-minded towards consuming insect-based meals
Exclusion Criteria:
- Anaemic (Hb < 12 g/dL)
- Inflammation (CRP > 5.0 mg/L)
- Pregnancy or intention to become pregnant during the study or within 30 days after the discontinuation of the study intervention
- Lactating up to 6 weeks before the study initiation
- Chronic digestive, renal and/or metabolic diseases
- Antibiotics in the last 4 weeks prior to the study and during the study
- Mineral and vitamin supplementation in the last 2 weeks prior to the study
- Chronic medication intake (except for oral contraceptives)
- Daily exercise routine of high intensity
- Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months
- Participation in any clinical study within the last 30 days
- Food allergies, especially hypersensitivity to crustacea, dust mites, sea food, gluten, milk, or eggs
- History of serious illness or infection within 3 months of the study
- Cigarette smoking (> 1 cigarette per day)
- Difficulties with blood or breath sampling
- Participants who cannot be expected to comply with study protocol (e.g., not available for the full 8.5 hours of the study day or unable to follow fasting period)
- Inability to understand the information sheet and the informed consent form due to cognitive or language reasons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 2H intrinsically-labeled T.molitor
1 portion of bread and vegetable soup prepared with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture
|
Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours.
The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
True ileal amino acid digestibility
Time Frame: 1st day
|
True ileal amino acid digestibility of intrinsically 2H labelled mealworm larvae (Tenebrio molitor) will be determined, relative to a simultaneously administered 13C labelled amino acids mixture, by measuring the plasma appearance of 13C and 2H isotopic enrichments of amino acids at plateau
|
1st day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemoglobin (Hb)
Time Frame: -14 days
|
Iron status marker
|
-14 days
|
|
C-Reactive Protein (CRP)
Time Frame: -14 days
|
inflammation status
|
-14 days
|
|
Appearance of 13CO2 enrichment in breath
Time Frame: 1st day
|
Rate of amino acid oxidation
|
1st day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Diego Moretti, Prof. Dr., Swiss Distance University of Applied Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 30, 2023
Primary Completion (Actual)
November 30, 2023
Study Completion (Actual)
April 16, 2024
Study Registration Dates
First Submitted
May 23, 2023
First Submitted That Met QC Criteria
May 23, 2023
First Posted (Actual)
June 1, 2023
Study Record Updates
Last Update Posted (Actual)
April 17, 2024
Last Update Submitted That Met QC Criteria
April 16, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TmD01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malnutrition; Protein
-
Mairaj NoorCompletedMalnutrition (Calorie) | Protein-energy MalnutritionPakistan
-
An Hsin QingShui ClinicCompleted
-
HAN University of Applied SciencesFrieslandCampina; HAS Hogeschool; Centre of Expertise Food (CoE Food); SligroCompletedMalnutrition; Protein | Protein MalnutritionNetherlands
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedKwashiorkor | Marasmus | Protein-energy MalnutritionJamaica
-
Alliance for International Medical ActionBien Être de La femme et de L'Enfant au NigerCompletedMalnutrition | Kwashiorkor | Marasmus | Malnutrition; Degree, ModerateNiger
-
Action Contre la FaimJohns Hopkins UniversityUnknown
-
University of ReadingBiotechnology and Biological Sciences Research Council; The Norwegian Institute... and other collaboratorsCompleted
-
Hospital General Universitario Gregorio MarañonInstituto de Salud Carlos III; European Regional Development Fund; Maternal,...UnknownProtein-Energy MalnutritionSpain
-
Assistance Publique - Hôpitaux de ParisCompletedProtein-Energy MalnutritionFrance
-
Washington University School of MedicineKamuzu University of Health SciencesWithdrawnKwashiorkor | MarasmusMalawi
Clinical Trials on 2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture
-
Vanderbilt University Medical CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMonoclonal Gammopathy of Undetermined Significance | Plasma Cell MyelomaUnited States
-
Thomas HopeCompletedProstate CancerUnited States
-
Sanjiv Sam GambhirNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Tongue Cancer | Stage... and other conditionsUnited States
-
Stanford UniversityWithdrawnCarotid Atherosclerosis | Aortic Aneurysm, AbdominalUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Switzerland
-
National Cancer Institute (NCI)WithdrawnT Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent B Lymphoblastic Lymphoma | Refractory B Lymphoblastic LymphomaUnited States, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Switzerland
-
National Cancer Institute (NCI)CompletedT Acute Lymphoblastic Leukemia | T Lymphoblastic LymphomaUnited States, Canada, Australia, New Zealand, Switzerland